Carina Biotech Limited
February 10, 2025
Gene/Cell Therapy
Carina Biotech is clinical stage, immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. Its lead candidate, CNA3103, targets LGR5 a cancer stem cell marker and is in development for the treatment of metastatic colon cancer, with early promising clinical results.
In addition to CNA3103, Carina has a pipeline of CAR-T programs as well as platform technologies for the positioning of CAR-T cells within solid tumors, to enhance potency and induce “serial” killing that is capable of memory. Carina also has a proprietary 5-day manufacturing process.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}